OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

CFO exercised or converted 2,500 UTHR derivative securities | OQRO

Home
Insider trades
United Therapeutics
CFO exercised or converted 2,500 UTHR derivative securities

Insider trades

Insider trade

CFO exercised or converted 2,500 UTHR derivative securities

Traded May 18, 2026 · Filed May 20, 2026

UTHUnited TherapeuticsUTHR

2,500
Derivative units

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: May 18, 2026
Reporting period: Not applicable
Filed with the SEC: May 20, 2026

CFOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001636178-26-000019

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

May 20, 2026, 12:32 AM UTC

Added to OQRO

Oct 6, 2026, 9:34 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

UNITED THERAPEUTICS Corp

Issuer CIK

1082554

Ticker

UTHR

Reporting person

James Edgemond

Relationship

Officer

Officer title

CFO AND TREASURER

Security

Stock Option

Table

Derivative (Table II)

Transaction date

May 18, 2026

Transaction code

Shares / units

2,500

Price per share

$0.00

Acquired / disposed

Disposed (D)

Shares owned after

Ownership form

Direct

Amendment

Footnotes from the filing

This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.

Around the same time

Paul A MahonEVP & GENERAL COUNSEL

Filed 4mo ago

8,300Shares · @ $146.03

Traded Jun 18 · filed 1 day later

Derivative exercise or conversion — not an open-market buy.

More Official record

Paul A Mahon (EVP & GENERAL COUNSEL) sold ~$921K of United Therapeutics

Scheduled in advanceFiled 4mo ago

Paul A Mahon (EVP & GENERAL COUNSEL) sold ~$515K of United Therapeutics

Scheduled in advanceFiled 4mo ago